SchA–p85–FAK complex dictates isoform-specific activation of Akt2 and subsequent PCBP1-mediated post-transcriptional regulation of TGFβ-mediated epithelial to mesenchymal transition in human lung cancer cell line A549

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7853-7859

  Xue, Xinying ^a,d   Wang, Xin ^e   Liu, Yuxia ^b   Teng, Guigen ^c   Wang, Yong ^a   Zang, Xuefeng ^a   Wang, Kaifei ^d   Zhang, Jinghui ^a   Xu, Yali ^a   Wang, Jianxin ^d,f   Pan, Lei ^a,f  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^f NONE   (China)

Author keywords

Akt2; Dab2; EMT; ILEI; Lung cancer; PCBP1; TGF

Indexed keywords

AKT2 PROTEIN, HUMAN; FOCAL ADHESION KINASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; ISOPROTEIN; PCBP1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA;

DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSFORMING GROWTH FACTOR BETA;

EID: 84922395014     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-1982-1     Document Type: Article

References (20)

1. American Cancer Society. Global cancer facts and figures, 2nd edition 2008. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf. Pg 15. Accessed 10 Sep 2012.
2. World Health Organization. Cancer fact sheet. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 10 Sep 2012.
3. van Zandwijk N. Neoadjuvant strategies for non-small cell lung cancer. Lung Cancer. 2001;34:s145–50.
4. Xiao DK, He JX. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2:154–9.
5. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.
6. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumor progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.
7. Chaudhury A, Hussey GS, Ray PS, et al. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010;12:286–93.
8. Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial–mesenchymal transition. Cancer Cell. 2009;15:402–15.
9. Warzecha CC, Shen S, Xing Y, et al. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol. 2009;6:546–62.
10. Hussey GS, Chaudhury A, Dawson AE, et al. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell. 2011;41:419–31.
11. Folgiero V, Di Carlo SE, Bon G, et al. Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. Cell Death Dis. 2012;3:e440.
12. Kawata M, Koinuma D, Ogami T, Umezawa K, Iwata C, Watabe T, et al. TGF-β-induced epithelial–mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J Biochem. 2012;151:205–16.
13. Ravichandran KS. Signaling via Shc family adapter proteins. Oncogene. 2001;20:6322–30.
14. Kavanaugh WM, Williams LT. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science. 1994;266:1862–5.
15. van der Geer P, Wiley S, Gish GD, et al. Identification of residues that control specific binding of the Shc phosphotyrosine-binding domain to phosphotyrosine sites. Proc Natl Acad Sci U S A. 1996;93:963–8.
16. Manning BD, Cantley LC. Hitting the target: emerging technologies in the search for kinase substrates. Sci STKE. 2002;2002:pe49.
17. Lawler S, Feng XH, Chen RH, et al. The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem. 1997;272:14850–9.
18. Rozakis-Adcock M, McGlade J, Mbamalu G, et al. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature. 1992;360:689–92.
19. Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol. 2007;20:135–41.
20. Sánchez-Margalet V, Goldfine ID, Truitt K, et al. Role of p85 subunit of phosphatidylinositol-3-kinase as an adaptor molecule linking the insulin receptor to insulin receptor substrate 1. Mol Endocrinol. 1995;9:435–42.